#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteochondrodysplasia Small intestine leiomyosarcoma Autoimmune haemolytic anaemia Biliary neoplasm Chorioretinitis Familial hypertriglyceridaemia Vulval cancer recurrent Paroxysmal nocturnal haemoglobinuria Vascular malformation Lung adenocarcinoma Philadelphia positive acute lymphocytic leukaemia Hyperadrenocorticism Pulmonary hypertension Ovarian cancer stage IV Fusarium infection More trials…

    Learn about Rare Diseases

    Tuberous sclerosis complex – Trials in Disease Undifferentiated sarcoma – Trials in Disease Hepatic angiosarcoma – Treatment Breast angiosarcoma – Treatment Encephalitis autoimmune – Diagnostics Urea cycle disorder – Life with Disease Hairy cell leukaemia Haemophilia A without inhibitors – Life with Disease Cytokine release syndrome – Trials in Disease Chordoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    COLESEVELAM HYDROCHLORIDE Asp1570 Masitinib Glucose Monohydrate Copper (64Cu) Chloride Rbl005.3 Anidulafungin [11C]Az14193391 Aon-D21 Molgramostim Octocog Alfa GRISNILIMAB SETARITOX Valproic Acid Taldefgrobep Alfa Mk-0616 Interferon Alfa Sunvozertinib INDAPAMIDE HEMIHYDRATE Oxacillin Valiltramiprosate More therapies…

    Learn about Your Condition

    Sjogren's syndrome Uveal melanoma Colon cancer stage IV Sciatica Dry mouth Bacterial vaginosis Implantation complication HER2 protein overexpression Herpes zoster Fibrous dysplasia of bone CDKL5 deficiency disorder Stress cardiomyopathy Rhabdoid tumour of the kidney Cervix carcinoma recurrent Hydrocele More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Ziekenhuis Gelderse Vallei Stichting

Ziekenhuis Gelderse Vallei Stichting

Willy Brandtlaan 10, Ede, 6716 RP, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

    Recruiting

    2 1
    Denmark Germany The Netherlands Spain

  • Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Pembrolizumab
    Austria Bulgaria France Germany Greece Italy +4

  • Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Gimeracil
    • Oteracil
    • Tegafur
    The Netherlands

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium France Germany Hungary Italy +3

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study on Letrozole and Gonadotropins for Women with Polycystic Ovary Syndrome (PCOS) to Improve Live Birth Rates

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Polycystic ovarian syndrome
    Investigated Drugs:
    • Follitropin Alfa
    • HUMAN MENOPAUSAL GONADOTROPHINS
    • Letrozole
    The Netherlands

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Obinutuzumab
    • Pirtobrutinib
    • Venetoclax
    Austria Belgium Czechia Denmark Finland France +8

  • Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    France The Netherlands

  • Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Elacestrant
    • Exemestane
    Austria Belgium Czechia Denmark Finland France +9
1 2 3 … 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!